Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Cardiff Oncology (CRDF) Stock Price & Analysis
1,463 Followers
CRDF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.94 - $6.42
Previous Close$3.63
Volume540.21K
Average Volume (3M)1.98M
Market Cap
$162.35M
Enterprise Value$89.68M
Total Cash (Recent Filing)$74.82M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)-4.0
Beta1.31
Next Earnings
Aug 08, 2024EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding44,724,591
10 Day Avg. Volume696,232
30 Day Avg. Volume1,984,070
Standard Deviation0.41
R-Squared0.07
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.44
Price to Sales (P/S)332.69
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue183.76
Enterprise Value/Gross Profit183.76
Enterprise Value/Ebitda-2.14
Forecast
1Y Price Target
$10.50Price Target Upside189.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cardiff Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesClinical update from Phase 2 ONSEMBLE trial in 2L RAS-mutant metastatic colorectal cancer reinforced earlier data, showing a 50% ORR in patients naive to Avastin.
Drug Approval PotentialCRDF-005 trial may position onvansertib for accelerated approval based on an ORR interim analysis.
Financial HealthCardiff's financial resources are believed to be sufficient to provide an operational runway into 3Q25.
Bears Say
Clinical Trial ProgressInitial CRDF-004 trial readout now expected in 2H24 due to a lower than anticipated pace of enrollment.
Clinical Trial StrategyThe randomized ONSEMBLE trial in 2L RAS+ CRC was halted, indicating a shift in company strategy.
Financial HealthCRDF reported a net loss of $9M.
---
Ownership Overview
27.17% Insiders
5.35% Mutual Funds
9.49% Other Institutional Investors
57.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $0.94 and its highest was $6.42 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Currently, no data Available
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Aug 08, 2024 which is in 81 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on May 02, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.248 by $0.028.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -$0.25.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 44,724,590 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.248. Following the earnings report the stock price went down -21.429%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Among the largest hedge funds holding Cardiff Oncology, Inc.’s share is Elkhorn Partners Limited Partnership. It holds Cardiff Oncology, Inc.’s shares valued at 198K.
---
Cardiff Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (189.26% Upside)
$10.50 (189.26% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 28.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.08%
12-Months-Change
Fundamentals
Return on Equity
-51.12%
Trailing 12-Months
Asset Growth
-30.51%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
---
CRDF Earnings Call
Q1 2024
0:00 / 0:00
---
CRDF Stock 12 Month Forecast
Average Price Target
$10.50
▲(189.26% Upside)
Technical Analysis
Best Analysts Covering CRDF
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+56.91%
reiterated a buy rating 13 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +56.91% per trade.
---